Guardant Health, Inc. $GH Shares Acquired by Assetmark Inc.

Assetmark Inc. lifted its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 48.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,718 shares of the company’s stock after acquiring an additional 6,461 shares during the quarter. Assetmark Inc.’s holdings in Guardant Health were worth $2,014,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Allworth Financial LP increased its stake in shares of Guardant Health by 19.5% during the third quarter. Allworth Financial LP now owns 844 shares of the company’s stock worth $53,000 after buying an additional 138 shares during the period. Eastern Bank lifted its stake in Guardant Health by 6.9% in the fourth quarter. Eastern Bank now owns 2,160 shares of the company’s stock worth $221,000 after acquiring an additional 139 shares during the last quarter. TD Waterhouse Canada Inc. lifted its stake in Guardant Health by 3.2% in the third quarter. TD Waterhouse Canada Inc. now owns 4,891 shares of the company’s stock worth $306,000 after acquiring an additional 151 shares during the last quarter. GAMMA Investing LLC grew its holdings in Guardant Health by 38.8% during the 4th quarter. GAMMA Investing LLC now owns 808 shares of the company’s stock worth $83,000 after acquiring an additional 226 shares in the last quarter. Finally, Guyasuta Investment Advisors Inc. increased its position in shares of Guardant Health by 3.9% in the 4th quarter. Guyasuta Investment Advisors Inc. now owns 7,000 shares of the company’s stock valued at $715,000 after purchasing an additional 260 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

GH has been the topic of a number of analyst reports. Guggenheim raised their price objective on shares of Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a report on Monday, January 26th. Barclays dropped their target price on Guardant Health from $130.00 to $115.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Robert W. Baird began coverage on Guardant Health in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price target on the stock. Citigroup lifted their price target on Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Friday, February 20th. Finally, JPMorgan Chase & Co. upped their price objective on Guardant Health from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Twenty equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $125.20.

Insider Transactions at Guardant Health

In other news, Director Musa Tariq sold 348 shares of the stock in a transaction that occurred on Wednesday, March 18th. The stock was sold at an average price of $88.09, for a total value of $30,655.32. Following the completion of the sale, the director directly owned 8,394 shares of the company’s stock, valued at approximately $739,427.46. This represents a 3.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Terilyn J. Monroe sold 3,832 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $92.68, for a total transaction of $355,149.76. Following the transaction, the insider directly owned 20,990 shares in the company, valued at $1,945,353.20. The trade was a 15.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 17,167 shares of company stock worth $1,753,633 in the last three months. Corporate insiders own 6.10% of the company’s stock.

Guardant Health Price Performance

Shares of GH opened at $91.07 on Tuesday. Guardant Health, Inc. has a 1-year low of $36.36 and a 1-year high of $120.74. The stock has a market cap of $11.95 billion, a PE ratio of -27.51 and a beta of 1.64. The firm has a fifty day moving average price of $92.25 and a 200 day moving average price of $95.04.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to the consensus estimate of $269.74 million. The business’s revenue was up 39.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.62) earnings per share. As a group, equities analysts expect that Guardant Health, Inc. will post -2.87 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.